BidaskClub Lowers Enanta Pharmaceuticals (NASDAQ:ENTA) to Hold

Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday, June 22nd, BidAskClub reports.

A number of other equities research analysts have also recently issued reports on ENTA. Wolfe Research began coverage on shares of Enanta Pharmaceuticals in a report on Friday, May 24th. They set an “outperform” rating and a $117.00 price target for the company. Berenberg Bank set a €126.00 ($146.51) price target on shares of Nemetschek and gave the company a “neutral” rating in a report on Tuesday, April 23rd. Finally, Zacks Investment Research upgraded shares of Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and an average target price of $111.20.

NASDAQ:ENTA traded down $1.98 during trading hours on Friday, reaching $84.83. The company’s stock had a trading volume of 172,072 shares, compared to its average volume of 230,374. The company has a market cap of $1.67 billion, a P/E ratio of 24.38 and a beta of 1.03. Enanta Pharmaceuticals has a one year low of $64.08 and a one year high of $127.20. The business has a 50-day moving average of $88.91.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.29. The firm had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $40.92 million. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. Enanta Pharmaceuticals’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.61 earnings per share. On average, research analysts predict that Enanta Pharmaceuticals will post 1.9 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of ENTA. WINTON GROUP Ltd increased its stake in Enanta Pharmaceuticals by 33.8% in the 2nd quarter. WINTON GROUP Ltd now owns 6,095 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 1,539 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Enanta Pharmaceuticals by 11.9% during the 1st quarter. First Trust Advisors LP now owns 25,234 shares of the biotechnology company’s stock worth $2,410,000 after buying an additional 2,681 shares during the period. FMR LLC boosted its holdings in shares of Enanta Pharmaceuticals by 19.5% during the 1st quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock worth $22,944,000 after buying an additional 39,200 shares during the period. Marshall Wace North America L.P. boosted its holdings in Enanta Pharmaceuticals by 1,128.7% in the 1st quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock valued at $21,558,000 after purchasing an additional 207,326 shares during the period. Finally, Trexquant Investment LP bought a new stake in Enanta Pharmaceuticals in the 1st quarter valued at about $1,433,000. 89.49% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Read More: Trading based on a resistance level

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.